Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company’s pipeline and financial resources, it has retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its promising pipeline and to maximize value for all stakeholders.

“With our best-in-class BLA-ready Fabry gene therapy program, differentiated zinc finger epigenetic regulation and capsid delivery platforms, and innovative MINT platform for large-scale genomic engineering, we have made the decision to explore alternatives to continue advancing these important assets to patients in need,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We look forward to working with Richard Hsieh and the rest of the Raymond James team to pursue a pathway that maximizes value for our stakeholders.”

Parties interested in discussing potential transactions with Sangamo should contact [e-mail].

Key Sangamo Assets and Status

Isaralgagene Civaparvovec (ST-920) Fabry Disease Gene Therapy

• Registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, an investigational gene therapy, is complete with 32 patients transitioned to the long-term follow-up study.
• Has Orphan Drug, Fast Track, and RMAT designations from U.S. Food and Drug Administration (FDA), Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency and Innovative Licensing and Access Pathway from U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
• Totality of data from the registrational STAAR study demonstrates the potential of isaralgagene civaparvovec as a one-time, well-tolerated and durable gene therapy treatment option for Fabry disease to provide meaningful, multi-organ clinical benefits that could fundamentally shift the Fabry treatment paradigm.
• Isaralgagene civaparvovec has a clear pathway to accelerated approval from the FDA, using mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study. The FDA has recently affirmed to Sangamo that two-year eGFR data may serve as confirmatory evidence for traditional approval.
• Rolling submission of the Biologics License Application (BLA) to the FDA has been initiated under the Accelerated Approval pathway, with the first two modules submitted.

Schreibe Deinen Kommentar